FDA Panel To Weigh Non-Inferiority Trial Margin In Review Of J&J’s Antibiotic Doribax
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Anti-Infective Drugs Advisory Committee will consider the merits of a 20 percent non-inferiority margin based on clinical response in patients with nosocomial and ventilator-associated pneumonia.
You may also be interested in...
J&J’s Doribax Is Subject Of FDA’s First “Complete Response” For An NDA
End of FDA’s “approvable” and “not approvable” era means less guidance for determining the prospects for an application after an initial rejection.
J&J’s Doribax Is Subject Of FDA’s First “Complete Response” For An NDA
End of FDA’s “approvable” and “not approvable” era means less guidance for determining the prospects for an application after an initial rejection.
J&J’s Doribax Is Subject Of FDA’s First "Complete Response" To An NDA
FDA is seeking additional information on Johnson & Johnson's Doribax (doripenem) prior to approving the antibiotic for the treatment of hospital-acquired pneumonia, including ventilator-associated pneumonia, the company announced Aug. 21